FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE)
CUSIP: 31189P102
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 122,342,805
- Total 13F shares
- 79,555,724
- Share change
- -16,841,459
- Total reported value
- $88,833,451
- Put/Call ratio
- 7.5%
- Price per share
- $1.12
- Number of holders
- 136
- Value change
- -$17,593,195
- Number of buys
- 70
- Number of sells
- 59
Quarterly Holders Quick Answers
What is CUSIP 31189P102?
CUSIP 31189P102 identifies FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 31189P102:
Top shareholders of FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
|
Company |
6.9%
|
7,852,183
|
$10,600,447 | $0 | 31 Mar 2025 | |
| Redmile Group, LLC |
13F
|
Company |
11%
|
12,872,946
|
$10,170,915 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
8.4%
|
10,310,453
|
$8,145,258 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
13D/G
|
Company |
0.82%
from 13D/G
|
7,794,513
|
$6,158,443 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.5%
|
4,289,159
|
$3,388,865 | — | 31 Mar 2025 | |
| J. Scott Wolchko |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
871,248
mixed-class rows
|
$2,987,354 | — | 01 Feb 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
2.8%
|
3,398,283
|
$2,684,983 | — | 31 Mar 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
2.8%
|
3,379,064
|
$2,669,798 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
2.7%
|
3,258,402
|
$2,574,463 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13D/G
13F
|
THE GOLDMAN SACHS GROUP, INC. · Company |
2%
|
2,274,020
|
$2,546,902 | -$6,958,784 | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
2.1%
|
2,591,558
|
$2,047,996 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
2.1%
|
2,515,850
|
$1,987,773 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
2%
|
2,473,565
|
$1,952,000 | — | 31 Mar 2025 | |
| Edward J. Dulac III |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
526,479
mixed-class rows
|
$1,948,742 | — | 04 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
2,269,609
|
$1,793,565 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.8%
|
2,240,058
|
$1,769,870 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
1.8%
|
2,203,323
|
$1,740,846 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.7%
|
2,110,065
|
$1,667,162 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
1.6%
|
1,937,133
|
$1,530,528 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.5%
|
1,867,773
|
$1,475,727 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.4%
|
1,680,580
|
$1,327,826 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
1.3%
|
1,551,081
|
$1,225,354 | — | 31 Mar 2025 | |
| Jerome Charles Bressi |
3/4/5
|
Chief Regulatory and Quality Officer |
—
mixed-class rows
|
585,203
mixed-class rows
|
$1,202,065 | — | 15 Jan 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.2%
|
1,424,167
|
$1,125,234 | — | 31 Mar 2025 | |
| Monaco Asset Management SAM |
13F
|
Company |
0.94%
|
1,149,708
|
$908,384 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.65%
|
794,973
|
$628,108 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.64%
|
787,000
|
$621,809 | — | 31 Mar 2025 | |
| Yu-Waye Chu |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
140,676
|
$614,754 | — | 18 Apr 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.58%
|
703,825
|
$556,092 | — | 31 Mar 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.57%
|
700,000
|
$553,070 | — | 31 Mar 2025 | |
| Mark Plavsic |
3/4/5
|
Chief Technical Officer |
—
class O/S missing
|
123,705
|
$540,591 | — | 10 Jan 2023 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.48%
|
585,025
|
$462,228 | — | 31 Mar 2025 | |
| Bruce & Co., Inc. |
13F
|
Company |
0.45%
|
550,000
|
$434,500 | — | 31 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.38%
|
459,308
|
$362,899 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.35%
|
433,192
|
$342,265 | — | 31 Mar 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.34%
|
411,332
|
$324,994 | — | 31 Mar 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.32%
|
397,177
|
$313,810 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.32%
|
388,443
|
$306,870 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.31%
|
379,088
|
$299,518 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.3%
|
367,285
|
$290,192 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.28%
|
342,236
|
$270,401 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.26%
|
314,877
|
$248,784 | — | 31 Mar 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.25%
|
302,899
|
$239,320 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.24%
|
291,755
|
$230,515 | — | 31 Mar 2025 | |
| Neelufar Mozaffarian |
3/4/5
|
Director |
—
class O/S missing
|
55,000
|
$218,400 | — | 29 May 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.2%
|
241,872
|
$191,103 | — | 31 Mar 2025 | |
| Powl Brian T. |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
41,146
|
$179,808 | — | 05 Jul 2023 | |
| Invesco Ltd. |
13F
|
Company |
0.17%
|
213,503
|
$168,689 | — | 31 Mar 2025 | |
| Yuan Xu |
3/4/5
|
Director |
—
mixed-class rows
|
63,669
mixed-class rows
|
$145,870 | — | 29 May 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.14%
|
177,360
|
$140,132 | — | 31 Mar 2025 |
Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q2 2025
As of 30 Jun 2025,
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) was held by
136 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
79,555,724 shares.
The largest 10 holders included
Redmile Group, LLC, BlackRock, Inc., VANGUARD GROUP INC, CITADEL ADVISORS LLC, JOHNSON & JOHNSON, Vestal Point Capital, LP, GOLDMAN SACHS GROUP INC, BAKER BROS. ADVISORS LP, ACADIAN ASSET MANAGEMENT LLC, and DIMENSIONAL FUND ADVISORS LP.
This page lists
136
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
127
Q2 2025 holders
136
Holder diff
9
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.